1.Kryger, M, Roth, T, Dement, W, eds. Principles and Practice of Sleep Medicine, 5th Edition. Philadelphia: Elsevior Saunders, 2010.
2.Lee-Chong, T, ed. Sleep Medicine: Essentials and Review. New York: Oxford, 2008.
3.Silber, M, Krahn, L, Morgenthaler, T, eds. Sleep Medicine in Clinical Practice New York: Informa Healthcare, 2010.
4.Grenberg, G, Watson, R, Deptula, D. Neuropsychological dysfunction in sleep apnea. Sleep 1987;10:254–362.
5.Engelman, H, Martin, S, Deary, J, Douglas, N. Effect of continuous positive airway pressure treatment on daytime function in sleep apnea/hypopnea syndrome. Lancet 1994;343:572–575.
6.Engelman, H, Martin, S, Deary, J, Douglas, N. Effict of CPAP therapy on daytime function in patients with mild sleep apnea/hypopnea syndrome. Thorax 1997;52:114–119.
7.Engelman, H, Martin, S, Kingshott, R, et al. Randomized placebo controlled trial of daytime function after continuous positive airway pressure (CPAP) therapy for the sleep apnea/hypopnoea syndrome. Thorax 1998;53:341–345.
8.Engelman, H, Kingshott, R, Wraith, P, et al. Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999;159:461–467.
9.Ferguson, K, Ono, T, Lowe, A, Keenan, S, Fleetham, J. A randomized crossover study of an oral appliance vs nasal continuous positive airway pressure in the treatment of mild-moderate obstructive sleep apnea. Chest 1996;109:1269–1275.
10.Ferguson, K, Ono, T, Lowe, A, Al-Majed, S, Love, L, Fleetham, J. A short term controlled trial of an adjustable oral appliance for the treatment of mild to moderate obstructive sleep apnea. Thorax 1997;52:362–368.
11.Borak, J, Cieslicki, J, Koziej, M, Matuszewski, A, Zielinski, J. Effect of CPAP treatment on psychological status in patients with severe obstructive sleep apnea. J Sleep Res 1996;5:123–127.
12.Clark, G, Blumenfeld, L, Yoffe, N, Peled, E, Lavie, P. A crossover study comparing the efficacy of continuous positive airway pressure with anterior mandibular positioning devices on patients with obstructive sleep apnea. Chest 1996;109:1477–1483.
13.Jenkinson, C, Stradling, J, Petersen, S. Comparison of three measures of quality of life outcome in the evaluation of continuous positive airway pressure for sleep apnea. J Sleep Res 1997;1997:199–204.
14.Jenkinson, C, Davies, R, Mullins, R, Stradling, J. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnea: A randomized prospective parallel trial. Lancet 1999;353:2100–2105.
15.Kribbs, N, Pack, A, Kline, L, et al. Effects of one night without nasal CPAP treatment on sleep and sleepiness in patients with obstructive sleep apnea. Am Rev Respir Dis 1993;147:1162–1168.
16.Kullen, A, Stepnowsky, C, Parker, L, Ancoli-Israel, S. Cognitive impairment and sleep disordered breathing. Sleep Res 1993;22:224.
17.Montplaisir, J, Bedard, M, Richer, F, Rouleau, I. Neurobehavioral manifestations in obstructive sleep apnea syndrome before and after treatment with continuous positive airway pressure. Sleep 1992;15:517–519.
18.Redline, S, Adams, N, Strauss, M, et al. Improvement of mild sleep disordered breathing with CPAP compared with conservative therapy. Am J Respir Crit Care Med 1998;157:858–865.
19.Weaver, T, Chugh, D, Maislin, G, et al. Changes in functional status after 3 months of CPAP treatment. Am J Respir Crit Care Med 1998;157:A53.
20.Bedard, M, Montplaisir, J, Malo, J, Richer, F, Rouleau, I. Persistent neuropsychological deficits and vigilance impairment in sleep apnea syndrome after treatment with continuous positive airway pressure (CPAP). J Clin Exp Neuropsychol 1993;15:330–341.
21.Munoz, X, Marti, S, Sumalla, J, Bosch, J, Sampol, G. Acute delirium as a manifestation of obstructive sleep apnea syndrome. Am J Resp Crit Care Med 1998;158:1306–1307.
22.Lee, J. Recurrent delirium associated with obstructive sleep apnea. Gen Hosp Psychiatry 1998;20:120–122.
23.Bliwise, D. Is sleep apnea a cause of reversible dementia in old age? J Am Geriatr Soc 1996;44:1407–1408.
24.Scheltens, P, Visscher, F, Van Keimpema, A, Lindeboom, J, Taphoorn, M, Wolter, E. Sleep apnea syndrome presenting with cognitive impairment. Neurology 1991;41:155–156.
25.Ancoli-Israel, S, Kripke, D, Klauber, M, Mason, W, Fell, R, Kaplan, O. Sleep-disordered breathing in community-dwelling elderly. Sleep 1991;14:486–495.
26.Yaffe, K, Laffan, A, Litwack Harrison, S, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 2011;306:613–619.
27.Osorio, R, Ayappa, I, Mantua, J. The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer’s disease in cognitively normal elderly individuals. Neurobiol Aging 2013;35:1318–1324.
28.Ju, Y, Lucey, B, Holtzman, D. Sleep and Alzheimer disease pathology – a bidirectional relationship. Nature Rev Neurol 2014;10:115–119.
29.Friedman, M, Ibrahim, H, Joseph, N. Staging of obstructive sleep apnea/hypopnea syndrome: a guide to appropriate treatment. Laryngoscope 2004;114:454–459.
30.Chung, F, Yegneswaran, B, Liao, P, et al. STOP questionnaire: A tool to screen patients for obstructive sleep apnea. Anesthesiology 2008;108:812–821.
31.Beninati, W, Harris, C, Herold, D, Shepard, JJ. The effect of snoring and obstructive sleep apnea on the sleep quality of bed partners. Mayo Clin Proc 1999;74:955–958.
32.Chong, M, Ayalon, L, Marler, M, et al. Continuous positive airway pressure reduces subjective daytime sleepiness in patients with mild to moderate Alzheimer’s disease with sleep disordered breathing. J Am Geriatr Soc 2006;54:777–781.
33.Ayalon, L, Ancoli-Israel, S, Stepnowsky, C, et al. Adherence to continuous positive airway pressure treatment in patients with Alzheimer’s disease and obstructive sleep apnea. Am J Geriatr Psychiatry 2006;14:176–180.
34.Colrain, I, Brooks, S, Black, J. A pilot evaluation of a nasal expiratory resistance device for the treatment of obstructive sleep apnea. J Clin Sleep Med 2008;4:426–433.
35.Thomas, R, Terzano, M, Parrino, L, Weiss, J. Obstructive sleep-disordered breathing with a dominant cyclic alternating pattern – a recognizable polysomnographic variant with practical clinical implications. Sleep 2004;27:229–234.
36.Pusalavidyasagar, S, Olson, E, Gay, P, Morgenthaler, T. Treatment of complex sleep apnea syndrome: a retrospective comparative review. Sleep Med 2006;7:474–479.
37.Morgenthaler, T, Gay, P, Gordon, N, Brown, L. Adaptive servoventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes. Sleep 2007;30:468–475.
38.Vitiello, M, Prinz, P. Alzheimer’s disease: Sleep and sleep/wake patterns. Clin Geriatr Med 1989 May;5(2):289–99.
39.Vitiello, M, Prinz, P, Williams, D, Frommlet, M, Ries, R. Sleep disturbances in patients with mild stage Alzheimer’s disease. J Gerontol 1990;45:M131–M138.
40.Bliwise, D, Carroll, J, Lee, K, Nekich, J, Dement, W. Sleep and “sundowning" in nursing home patients with dementia. Psych Res 1993;48:277–292.
41.Ancoli-Israel, S, Klauber, M, Jones, D, et al. Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep 1997;20:18–23.
42.Kang, J, Lim, M, Bateman, R, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009;326:1005–1007.
43.Lim, A, Kowgier, M, Yu, L, Buchman, A, Benett, D. Sleep fragmentation and the risk of incident Alzheimer’s disease and cognitive decline in order persons. Sleep 2013;36:1027–1032.
44.Skene, D, Swaab, D. Melatonin rhythmicity: effect of age and Alzheimer’s disease. Exp Gerontol 2003;38:199–206.
45.Singer, C, MacArthur, A, Hughes, R, Sack, R, Lewy, A. High-dose melatonin and sleep in the elderly. Sleep Research 1995;24A:151.
46.Brusco, L, Fainstein, I, Marquez, M, Cardinali, D. Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signal Recep 1999;8:126–131.
47.Singer, C, Tractenberg, R, Kaye, J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 2003;26:893–901.
48.Hozumi, S, Okawa, M, Mishima, K, Hishikawa, Y, Hori, H, Takahashi, K. Phototherapy for elderly patients with dementia and sleep-wake rhythm disorders: A comparison between morning and evening light exposure. Japan J Psych Neurol 1990;44:813–814.
49.Lyketsos, C, Lindell Veiel, L, Baker, A, Steele, C. A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. Internat J Ger Psychiatry 1999;14:520–525.
50.Satlin, A, Volicer, L, Ross, V, Herz, L, Campbell, S. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer’s disease. Am J Psychiatry 1992;149:1028–1032.
51.Van Someren, E, Kessler, A, Mirmiran, M, Swaab, D. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry 1997;41:955–963.
52.Thannickal, T, Lai, Y, Siegel, J. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 2007;130:1586–1595.
53.Ferman, T, Smith, G, Dickson, D, et al. Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer’s disease using the Multiple Sleep Latency Test. Alzheimer Res Ther 2014;16:76.
54.Gurian, B, Rosowsky, E. Low-dose methylphenidate in the very old. J Geriatr Psychiatry Neurol 1990;3:152–154.
55.Ben-Itzhak, R, Giladi, N, Gruendlinger, L, Hausdorff, J. Can methylphenidate reduce fall risk in community-living older adults? A double-blind, single-dose cross-over study. J Amer Geriatr Soc 2008;56:695–700.
56.Kuntz, K, Boeve, B, Drubach, D, Allen, L, Drubach, D. Safety, tolerability, and efficacy of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies. Neurology 2012;78 (Suppl 1):P04.192.
57.Olson, E, Boeve, B, Silber, M. Rapid eye movement sleep behavior disorder: demographic, clinical, and laboratory findings in 93 cases. Brain 2000;123:331–339.
58.Boeve, B. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann NY Acad Sci 2010;1184:17–56.
59.Postuma, R, Gagnon, J, Vendette, M, Fantini, M, Massicotte-Marquez, J, Montplaisir, J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72 1296–1300.
60.Iranzo, A, Molinuevo, J, Santamaría, J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572–577.
61.Boeve, BF, Silber, MH, Ferman, TJ, et al. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 1998;51:363–370.
62.Boeve, B, Silber, M, Ferman, T, Lucas, J, Parisi, J. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001;16:622–630.
63.Boeve, B, Silber, M, Ferman, T, et al. REM sleep behavior disorder in parkinson’s disease, dementia with lewy bodies, and multiple system atrophy. In Bedard, M, Agid, Y, Chouinard, S, Fahn, S, Korczyn, A, Lesperance, P, eds. Mental and Behavioral Dysfunction in Movement Disorders. Totowa: Humana Press, 2003: pp. 383–397.
64.Boeve, B, Silber, M, Parisi, J, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003;61:40–45.
65.Boeve, B, Silber, M, Ferman, T. REM sleep behavior disorder in Parkinson’s disease and dementia with Lewy bodies. J Ger Psychiatry Neurol 2004;17:146–157.
66.Boeve, B, Silber, M, Saper, C, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007;130:2770–2788.
67.Ferman, TJ, Boeve, BF, Smith, GE, et al. REM sleep behavior disorder and dementia: cognitive differences when compared with AD. Neurology 1999;52:951–957.
68.Ferman, T, Smith, G, Boeve, B, et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer’s disease. Clin Neuropsychol 2006;20.
69.Ferman, T, Boeve, B, Smith, G, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 2011;77:875–882.
70.Molano, J, Boeve, B, Ferman, T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: A clinicopathological study. Brain 2009;133:540–556.
71.Schenck, C, Boeve, B, Mahowald, M. Delayed emergence of a Parkinsonian disorder or dementia in 81% of older males initially diagnosed with idiopathic REM sleep behavior disorder (RBD): 16-year update on a previously reported series. Sleep Med 2013 Aug;14(8):744–748.
72.Iranzo, A, Fernandez-Arcos, A, Tolosa, E, et al. neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: Study in 174 patients. PLoS One 2014;9:e89741.
73.Postuma, R, Gagnon, J-F, Bertrand, J-A, Marchand, D, Montplaisir, J. Parkinson risk in idiopathic REM sleep behavior disorder. Neurology 2015;84:1104–1113.
74.Boeve, B. Predicting the future in idiopathic rapid-eye movement sleep behaviour disorder. Lancet Neurol 2010;9:1040–1042.
75.Boeve, B. Idiopathic REM sleep behaviour disorder in the development of Parkinson’s disease. Lancet Neurol 2013;12:469–482.
76.Postuma, RB, Gagnon, JF, Montplaisir, JY. REM sleep behavior disorder: From dreams to neurodegeneration. Neurobiol Dis 2012;46:553–558.
77.Schenck, C, Montplaisir, J, Frauscher, B, et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy – a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 2013;14:795–806.
78.Boeve, B, Molano, J, Ferman, T, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011;12:445–453.
79.Boeve, B, Molano, J, Ferman, T, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample. J Clin Sleep Med 2013;9:475–480.
80.Iranzo, A, Santamaria, J. Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep 2005;28:203–206.
81.McCarter, S, Boswell, C, St Louis, E, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med 2013 Mar;14(3):237–42.
82.Schenck, C, Mahowald, M. REM sleep behavior disorder: Clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep 2002;25:120–138.
83.Gagnon, J, Postuma, R, Montplaisir, J. Update on the pharmacology of REM sleep behavior disorder. Neurology 2006;67:742–747.
84.Kunz, D, Bes, F. Melatonin as a therapy in REM sleep behavior disorder patients: An open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999;14:507–511.
85.Boeve, B, Silber, M, Ferman, T. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003;4:281–284.
86.McGrane, I, Leung, J, St Louis, E, Boeve, B. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med 2015 Jan;16(1):19–26.
87.Reynolds, C, Kupfer, D, Hoch, C, Sewitch, D. Sleeping pills in the elderly: Are they ever justified? J Clin Psychiatry 1985;46:9–12.
88.Ringman, J, Simmons, J. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000;55:870–871.
89.Onofrj, M, Luciano, AL, Thomas, A, Iacono, D, D’Andreamatteo, G. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 2003;60:113–115.
90.Winkelman, J, James, L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 2004;15:317–321.
91.Arnulf, I, Bonnet, AM, Damier, P, et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology 2000;55:281–288.
92.Boeve, B. Dementia with Lewy bodies. In Petersen, R, ed. Continuum (Minneap Minn). Minneapolis: American Academy of Neurology, 2004: pp. 81–112.
93.McKeith, I, Dickson, D, Lowe, J, et al. Dementia with Lewy bodies: Diagnosis and management: Third report of the DLB Consortium. Neurology 2005;65:1863–1872.
94.Emre, M, Aarsland, D, Brown, R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007;22:1689–1707.
95.Boeve, B. Diagnosis and Management of the non-Alzheimer dementias. In Noseworthy, J, ed. Neurological Therapeutics: Principles and Practice, 2nd Edition. Abingdon: Informa Healthcare, 2006: pp. 3156–3206.
96.McKeith, I, Del Ser, T, Spano, P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.
97.Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351:2509–2518.
98.Herrmann, N, Rabheru, K, Wang, J, Binder, C. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials Am J Geriatr Psychiatry 2005;13:527–534.
99.Cummings, J, Schneider, E, Tariot, P, Graham, S, Group MM-M-S. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57–63.
100.Cummings, J, McRae, T, Zhang, R, Group. D-SS. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006;14:605–612.